INS and type 1 diabetes mellitus: In adults with T1D, there was an increase in the use of CGM (5% [95% CI, 5%-5%] to 57% [95% CI, 57%-57%]; P < .001 for trend), insulin pumps (11% [95% CI, 11%-12%] to 29% [95% CI, 29%-29%]; P < .001 for trend), and both devices concurrently (1% [95% CI, 1%-1%] to 22% [95% CI, 22%-23%]; P < .001 for trend) from the 2009-2011 to 2021-2023 study periods (Figure 3B).